Last reviewed · How we verify
[14C] HQP1351
HQP1351 is a novel third-generation BCR-ABL inhibitor developed by Ascentage Pharma for the treatment of chronic myeloid leukemia (CML). It addresses resistance to first and second-generation inhibitors, offering potential benefits in refractory cases. Currently in clinical development, it has not yet received regulatory approval.
At a glance
| Generic name | [14C] HQP1351 |
|---|---|
| Sponsor | Ascentage Pharma Group Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- [14C] HQP1351 CI brief — competitive landscape report
- [14C] HQP1351 updates RSS · CI watch RSS
- Ascentage Pharma Group Inc. portfolio CI